LEXINGTON, Mass.--(BUSINESS WIRE)--A study published in the current edition of Clinical Pharmacokinetics, a peer-reviewed scientific journal, reports that two different combinations of individual isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HYD), used in the Vasodilator-Heart Failure Trials (V-HeFT) I and II are not bioequivalent to BiDil®, the fixed-dose combination of ISDN and HYD, used in the African American Heart Failure Trial (A-HeFT). The study compared identical amounts of the formulations of ISDN and HYD used in V-HeFT I and II, and BiDil, the proprietary fixed dose combination, used in A-HeFT and demonstrated that the formulations used in V-HeFT I and V-HeFT II are neither bioequivalent to each other, nor to BiDil.
